| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
An antisense oligonucleotide targeting TGF-β2 inhibits lung metastasis and induces CD86 expression in tumor-associated macrophages
|
Huber-Ruano, I.
|
|
|
28 |
9 |
p. 2278-2285
|
artikel
|
| 2 |
Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide
|
Rathkopf, D.E.
|
|
|
28 |
9 |
p. 2264-2271
|
artikel
|
| 3 |
A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer
|
Ajani, J.A.
|
|
|
28 |
9 |
p. 2142-2148
|
artikel
|
| 4 |
A randomized, open-label, multicenter, phase 3 study to compare the efficacy and safety of eribulin to treatment of physician’s choice in patients with advanced non-small cell lung cancer
|
Katakami, N.
|
|
|
28 |
9 |
p. 2241-2247
|
artikel
|
| 5 |
Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease
|
Lim, S.H.
|
|
|
28 |
9 |
p. 2199-2205
|
artikel
|
| 6 |
Borderline resectable pancreatic cancer: an evolving concept
|
Petrucciani, N.
|
|
|
28 |
9 |
p. 2315
|
artikel
|
| 7 |
Borderline resectable pancreatic cancer: conceptual evolution and current approach to image-based classification
|
Gilbert, J.W.
|
|
|
28 |
9 |
p. 2067-2076
|
artikel
|
| 8 |
Cancer mortality predictions for 2017 in Latin America
|
Carioli, G.
|
|
|
28 |
9 |
p. 2286-2297
|
artikel
|
| 9 |
Can we trust burnout research?
|
Bianchi, R.
|
|
|
28 |
9 |
p. 2320-2321
|
artikel
|
| 10 |
Chemotherapy-induced toxicity—a secondary effect caused by released DNA?
|
Helleday, T.
|
|
|
28 |
9 |
p. 2054-2055
|
artikel
|
| 11 |
Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment
|
Thierry, A.R.
|
|
|
28 |
9 |
p. 2149-2159
|
artikel
|
| 12 |
Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT
|
Regan, M.M.
|
|
|
28 |
9 |
p. 2225-2232
|
artikel
|
| 13 |
Consolidative proton therapy after chemotherapy for patients with Hodgkin lymphoma
|
Hoppe, B.S.
|
|
|
28 |
9 |
p. 2179-2184
|
artikel
|
| 14 |
Development of an integrated electronic platform for patient self-report and management of adverse events during cancer treatment
|
Holch, P.
|
|
|
28 |
9 |
p. 2305-2311
|
artikel
|
| 15 |
Do not throw the baby out with the bathwater: SELECT a personalized, de-escalated lenvatinib schedule allows response in locally advanced DTC while controlling major drug-related bleeding
|
Resteghini, C.
|
|
|
28 |
9 |
p. 2321-2322
|
artikel
|
| 16 |
Early-stage mantle cell lymphoma: a retrospective analysis from the International Lymphoma Radiation Oncology Group (ILROG)
|
Dabaja, B.S.
|
|
|
28 |
9 |
p. 2185-2190
|
artikel
|
| 17 |
Editorial board
|
|
|
|
28 |
9 |
p. ii-iii
|
artikel
|
| 18 |
Evaluation of the impact of tumor HPV status on outcome in patients with locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) receiving cisplatin, 5-fluorouracil with or without docetaxel: a subset analysis of EORTC 24971 study
|
Psyrri, A.
|
|
|
28 |
9 |
p. 2213-2218
|
artikel
|
| 19 |
Forcing the vicious circle: sarcopenia increases toxicity, decreases response to chemotherapy and worsens with chemotherapy
|
Bozzetti, F.
|
|
|
28 |
9 |
p. 2107-2118
|
artikel
|
| 20 |
From academia to industry: a road more travelled
|
Pao, W.
|
|
|
28 |
9 |
p. 2312-2314
|
artikel
|
| 21 |
How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials
|
Bonnetain, F.
|
|
|
28 |
9 |
p. 2077-2085
|
artikel
|
| 22 |
Immune oncology and neuroendocrine tumors
|
Chauhan, A.
|
|
|
28 |
9 |
p. 2322-2323
|
artikel
|
| 23 |
Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II–III trial
|
Ghi, M.G.
|
|
|
28 |
9 |
p. 2206-2212
|
artikel
|
| 24 |
International cancer seminars: a focus on esophageal squamous cell carcinoma
|
Murphy, G.
|
|
|
28 |
9 |
p. 2086-2093
|
artikel
|
| 25 |
Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisions
|
Mayo-de-las-Casas, C.
|
|
|
28 |
9 |
p. 2248-2255
|
artikel
|
| 26 |
Maintenance therapy in advanced colorectal cancer, yes or no? Ask the laboratory
|
Sobrero, A.
|
|
|
28 |
9 |
p. 2043-2044
|
artikel
|
| 27 |
Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study
|
Goey, K.K.H.
|
|
|
28 |
9 |
p. 2128-2134
|
artikel
|
| 28 |
Metastasis of cancer: when and how?
|
Lee, W.-C.
|
|
|
28 |
9 |
p. 2045-2047
|
artikel
|
| 29 |
Multiregion whole-exome sequencing of matched primary and metastatic tumors revealed genomic heterogeneity and suggested polyclonal seeding in colorectal cancer metastasis
|
Wei, Q.
|
|
|
28 |
9 |
p. 2135-2141
|
artikel
|
| 30 |
Oncologist use and perception of large panel next-generation tumor sequencing
|
Schram, A.M.
|
|
|
28 |
9 |
p. 2298-2304
|
artikel
|
| 31 |
Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma
|
Dreyling, M.
|
|
|
28 |
9 |
p. 2169-2178
|
artikel
|
| 32 |
Pooled analysis of two randomized, double-blind trials comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer
|
Blackwell, K.
|
|
|
28 |
9 |
p. 2272-2277
|
artikel
|
| 33 |
Prediction of pathological response to neoadjuvant treatment in rectal cancer with a two-protein immunohistochemical score derived from stromal gene-profiling
|
Gonçalves-Ribeiro, S.
|
|
|
28 |
9 |
p. 2160-2168
|
artikel
|
| 34 |
Prevention of chemotherapy toxicity by agents that neutralize or degrade cell-free chromatin
|
Mittra, I.
|
|
|
28 |
9 |
p. 2119-2127
|
artikel
|
| 35 |
Proton therapy in mediastinal Hodgkin lymphoma: moving from dosimetric prediction to clinical evidence
|
Ricardi, U.
|
|
|
28 |
9 |
p. 2049-2050
|
artikel
|
| 36 |
Reduced-intensity versus reduced-toxicity myeloablative fludarabine/busulfan-based conditioning regimens for allografted non-Hodgkin lymphoma adult patients: a retrospective study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire
|
Le Bourgeois, A.
|
|
|
28 |
9 |
p. 2191-2198
|
artikel
|
| 37 |
Reply to the letter to the editor ‘Borderline resectable pancreatic cancer: an evolving concept’ by Petrucciani et al.
|
Gilbert, J.W.
|
|
|
28 |
9 |
p. 2316
|
artikel
|
| 38 |
Revival of PI3K inhibitors in non-Hodgkin’s lymphoma
|
Batlevi, C.L.
|
|
|
28 |
9 |
p. 2047-2049
|
artikel
|
| 39 |
Rituximab for nivolumab plus ipilimumab-induced encephalitis in a small-cell lung cancer patient
|
Ito, M.
|
|
|
28 |
9 |
p. 2318-2319
|
artikel
|
| 40 |
Stromal inflammation, necrosis and HER2 overexpression in ductal carcinoma in situ of the breast: another causality dilemma?
|
Van Bockstal, M.
|
|
|
28 |
9 |
p. 2317
|
artikel
|
| 41 |
Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer
|
Hamy, A.-S.
|
|
|
28 |
9 |
p. 2233-2240
|
artikel
|
| 42 |
Survival advantage for etoposide/cisplatin over paclitaxel/carboplatin concurrent chemoradiation in patients with inoperable stage III NSCLC: a subgroup analysis for ECOG 2 patients would be of great interest
|
Manapov, F.
|
|
|
28 |
9 |
p. 2319-2320
|
artikel
|
| 43 |
Table of Contents
|
|
|
|
28 |
9 |
p. iv-vii
|
artikel
|
| 44 |
The ‘critical mass’ survey of palliative care programme at ESMO designated centres of integrated oncology and palliative care
|
Hui, D.
|
|
|
28 |
9 |
p. 2057-2066
|
artikel
|
| 45 |
The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC
|
Aguiar Jr, P N
|
|
|
28 |
9 |
p. 2256-2263
|
artikel
|
| 46 |
The Italian Collaborative Group sets a standard for the treatment of locally advanced head and neck cancer
|
Misiukiewicz, K.
|
|
|
28 |
9 |
p. 2051-2054
|
artikel
|
| 47 |
TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase II EORTC trial
|
Specenier, P.M.
|
|
|
28 |
9 |
p. 2219-2224
|
artikel
|
| 48 |
Treating cancer cachexia: an evolving landscape
|
Laird, B.
|
|
|
28 |
9 |
p. 2055-2056
|
artikel
|
| 49 |
Unmet needs in the first-line treatment of follicular lymphoma
|
Casulo, C.
|
|
|
28 |
9 |
p. 2094-2106
|
artikel
|
Tijdschrift beschrijving